

**Supplementary table 1** Demographics and baseline characteristics of evaluable participants

<b>Characteristic</b>	<b>Number (%) of participants N=6004</b>
<b>Age (Years)</b>	
Mean $\pm$ SD	28.8 $\pm$ 10
Median	25
Range	14 - 82
<b>Sex</b>	
Female	5266 (87.7%)
Male	738 (12.3%)
<b>Ethnicity</b>	
Hispanic/Latino	1273 (21.2%)
Not Hispanic/Not Latino	4577 (76.2%)
Unknown	154 (2.6%)
<b>Race</b>	
American Indian/Alaskan Native	28 (0.5%)
Asian	131 (2.2%)
Black/African-American	2718 (45.3%)
Native Hawaiian/Pacific Islander	25 (0.4%)
White	2786 (46.4%)
Other	283 (4.7%)
Unknown	33 (0.5%)
<b>Self-Described Symptom Status</b>	
Symptomatic	2255 (37.6%)
Asymptomatic	3749 (62.4%)
<b>Self-Reported Pregnancy Status (Female Only)</b>	
Pregnant	202 (3.8%)
Not Pregnant	4970 (94.4%)
Unknown	94 (1.8%)
<b>Clinic Type</b>	
Family Planning	2312 (38.5%)
Obstetrics/Gynaecology	1371 (22.8%)
Sexually Transmitted Infection	2321 (38.7%)

Note: Participants with designated infection status and valid **cobas**<sup>®</sup> CT/NG v2.0 Test results are considered evaluable and included in this summary table.

Note: Unknown category indicates participants for whom the corresponding information is not available.



Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>			cobas CT/NG Test					Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR	PC Pre	SW	UR	VG	PC Pre	PC Post	Symp	Asymp	
Infected	+	+	+	-	+	NA	+	+	+	+	0	1	1
Infected	+	+	+	-	-	+	+	+	-	-	0	1	1
Infected	+	+	+	-	-	-	+	NA	-	NA	0	1	1
Infected	+	+	+	NA	+	+	+	+	+	+	1	0	1
Infected	+	-	+	+	+	+	+	+	+	-	0	1	1
Infected	+	-	+	+	+	+	+	+	+	NA	1	0	1
Infected	+	-	+	+	+	+	+	-	+	+	0	1	1
Infected	+	-	+	+	+	+	-	-	+	+	1	0	1
Infected	+	-	+	+	+	NA	+	+	+	-	1	0	1
Infected	+	-	+	-	+	+	+	+	+	+	0	1	1
Infected	+	-	+	-	+	+	-	+	+	-	0	1	1
Infected	+	-	+	-	+	+	-	-	+	+	1	0	1
Infected	+	-	+	-	+	-	-	+	-	-	0	1	1
Infected	+	-	+	-	-	+	-	+	+	+	0	1	1
Infected	+	-	+	-	-	-	-	NA	-	-	0	1	1
Infected	+	-	+	-	NA	+	+	+	-	-	0	1	1
Infected	+	-	+	NA	+	+	-	-	-	-	1	0	1
Infected	+	NA	+	NA	+	+	NA	+	NA	NA	1	0	1
Infected	-	+	+	+	+	+	+	+	-	+	1	0	1
Infected	-	+	+	+	+	-	+	+	+	+	1	0	1
Infected	-	+	+	+	+	-	+	+	-	+	0	1	1
Infected	-	+	+	+	+	-	+	-	-	-	1	0	1
Infected	-	+	+	+	-	-	+	+	+	-	0	1	1
Infected	-	+	+	+	-	-	-	+	+	-	1	0	1
Infected	-	+	-	+	+	+	+	+	+	-	1	0	1
Infected	-	+	-	+	-	+	+	+	-	+	0	1	1
Infected	-	+	-	+	-	-	+	+	+	+	1	0	1
Infected	-	+	-	+	-	-	+	+	-	+	1	0	1
Infected	-	+	-	+	NA	-	+	-	NA	NA	0	1	1
Infected	-	+	NA	+	-	+	+	+	-	-	0	1	1
Infected	-	+	+	-	-	-	-	+	-	-	0	1	1
<b>Total Infected</b>											<b>162</b>	<b>203</b>	<b>365</b>
Non-Infected	-	-	-	-	-	-	-	-	-	-	1575	2561	4136
Non-Infected	-	-	-	-	-	-	-	-	-	NA	57	178	235
Non-Infected	-	-	-	-	-	NA	-	-	-	-	27	30	57
Non-Infected	-	-	-	-	-	-	-	NA	-	-	26	27	53
Non-Infected	-	-	-	-	-	-	NA	-	-	-	23	26	49
Non-Infected	-	-	-	-	NA	-	-	-	NA	NA	17	28	45
Non-Infected	-	-	-	-	-	-	NA	-	-	NA	3	37	40
Non-Infected	-	-	-	-	-	-	-	-	NA	-	5	32	37
Non-Infected	-	-	-	-	-	-	-	-	NA	NA	10	18	28

Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>			cobas CT/NG Test					Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR	PC Pre	SW	UR	VG	PC Pre	PC Post	Symp	Asymp	
Non-Infected	-	-	-	-	-	NA	NA	-	-	-	1	18	19
Non-Infected	NA	NA	-	-	-	NA	-	-	-	-	0	16	16
Non-Infected	-	-	-	-	-	NA	-	NA	-	-	2	13	15
Non-Infected	-	-	+	-	-	-	-	-	-	-	8	6	14
Non-Infected	-	-	-	-	-	NA	-	-	-	NA	1	12	13
Non-Infected	-	-	-	-	-	-	-	+	-	-	7	5	12
Non-Infected	-	-	-	-	-	-	+	-	-	-	4	7	11
Non-Infected	-	-	-	-	-	NA	NA	-	-	NA	1	9	10
Non-Infected	NA	-	-	-	-	-	-	-	-	-	3	7	10
Non-Infected	-	-	-	-	-	+	-	-	-	-	7	2	9
Non-Infected	+	-	-	-	-	-	-	-	-	-	2	5	7
Non-Infected	-	-	-	+	-	-	-	-	-	-	4	3	7
Non-Infected	-	-	-	-	-	-	-	-	-	+	1	6	7
Non-Infected	-	-	-	-	+	-	-	-	-	-	1	5	6
Non-Infected	-	-	-	-	-	NA	NA	NA	-	-	3	3	6
Non-Infected	-	-	-	-	-	-	-	-	+	-	2	3	5
Non-Infected	-	+	-	-	-	-	-	-	-	-	0	4	4
Non-Infected	-	-	-	-	-	-	NA	-	NA	NA	1	2	3
Non-Infected	-	-	-	NA	-	-	-	-	-	-	2	1	3
Non-Infected	-	-	-	-	+	-	-	-	+	-	0	2	2
Non-Infected	-	-	NA	-	-	-	-	-	-	-	0	2	2
Non-Infected	-	NA	-	-	-	-	-	-	-	-	1	1	2
Non-Infected	NA	NA	-	-	-	NA	-	-	NA	-	0	2	2
Non-Infected	+	+	-	-	-	+	-	+	-	+	1	0	1
Non-Infected	+	-	-	-	+	+	-	+	+	+	1	0	1
Non-Infected	+	-	-	-	+	-	-	+	+	+	1	0	1
Non-Infected	+	-	-	-	-	+	-	+	-	-	0	1	1
Non-Infected	+	-	-	-	-	+	-	-	-	-	1	0	1
Non-Infected	-	+	-	-	-	-	NA	-	-	-	1	0	1
Non-Infected	-	-	+	+	+	+	+	+	+	+	0	1	1
Non-Infected	-	-	+	+	-	+	+	+	-	-	1	0	1
Non-Infected	-	-	+	+	-	-	-	+	-	-	1	0	1
Non-Infected	-	-	+	+	-	-	-	-	+	-	0	1	1
Non-Infected	-	-	-	+	+	-	+	+	+	-	0	1	1
Non-Infected	-	-	-	+	-	-	+	-	-	-	1	0	1
Non-Infected	-	-	+	-	+	-	-	+	+	+	0	1	1
Non-Infected	-	-	+	-	-	-	-	+	-	-	1	0	1
Non-Infected	-	-	+	-	-	-	-	-	-	+	1	0	1
Non-Infected	-	-	+	-	-	-	NA	NA	-	-	1	0	1
Non-Infected	-	-	-	-	+	+	-	-	-	+	1	0	1
Non-Infected	-	-	-	-	+	-	-	-	-	NA	0	1	1

Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>			cobas CT/NG Test					Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR	PC Pre	SW	UR	VG	PC Pre	PC Post	Symp	Asymp	
Non-Infected	-	-	-	-	+	-	-	NA	-	-	0	1	1
Non-Infected	-	-	-	-	-	+	+	-	-	-	0	1	1
Non-Infected	-	-	-	-	-	+	-	+	-	-	1	0	1
Non-Infected	-	-	-	-	-	-	-	+	+	-	0	1	1
Non-Infected	-	-	-	-	-	-	-	+	-	NA	1	0	1
Non-Infected	-	-	-	-	-	-	-	NA	-	+	0	1	1
Non-Infected	-	-	-	-	-	-	-	NA	-	NA	0	1	1
Non-Infected	-	-	-	-	-	-	NA	-	+	NA	0	1	1
Non-Infected	-	-	-	-	-	-	NA	NA	-	-	0	1	1
Non-Infected	-	-	-	-	-	NA	-	NA	NA	NA	1	0	1
Non-Infected	-	-	-	-	-	NA	NA	-	NA	-	0	1	1
Non-Infected	-	-	-	-	-	NA	NA	-	NA	NA	1	0	1
Non-Infected	-	-	-	-	-	NA	NA	NA	-	NA	1	0	1
Non-Infected	-	-	NA	-	NA	-	-	-	NA	NA	1	0	1
Non-Infected	-	-	-	NA	NA	NA	NA	NA	-	-	1	0	1
Non-Infected	-	NA	-	-	-	-	-	-	-	NA	1	0	1
Non-Infected	NA	NA	-	-	-	-	-	-	-	-	0	1	1
<b>Total Non-Infected</b>											<b>1814</b>	<b>3086</b>	<b>4900</b>

<sup>a</sup> NAAT1 = BD ProbeTec CT Q<sup>x</sup> and GC Q<sup>x</sup> Amplified DNA Assays, NAAT2 = Gen-Probe APTIMA Combo2 Assay.

<sup>b</sup> Symp = symptomatic, Asymp = asymptomatic.

Note: Subjects are designated as being infected with CT if at least 2 predicate NAATs with different target regions give positive results in the endocervical swab and/or the urine specimen. However, females are categorised as non-infected for any swab specimen if the swab specimens and the PreservCyt specimen (NAAT2) were negative and the urine specimens were positive.

Note: Subjects with designated infection status and valid **cobas** CT/NG Test results are considered evaluable and included in this summary table.

Note: + denotes Positive; - denotes Negative; NA indicates specimen was not obtained or available for testing.

Note: SW = endocervical swab, UR = urine, VG = vaginal swab, PC Pre = PreservCyt (pre-aliquot), PC Post = PreservCyt (post-aliquot).

**Supplementary table 2b** *C. trachomatis* Positive/Negative Analysis for Male Patient Infected Status for the VENUS II trial

Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>		cobas CT/NG Test	Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR	UR	Symp	Asymp	
Infected	+	+	+	+	+	64	43	107
Infected	-	+	-	+	+	3	3	6
Infected	-	+	+	+	+	0	3	3
Infected	+	+	+	-	+	1	1	2
Infected	+	-	+	-	-	0	1	1
Infected	+	-	+	+	+	0	1	1
Infected	-	+	+	-	+	1	0	1
Infected	-	+	-	+	-	1	0	1
<b>Total Infected</b>						<b>70</b>	<b>52</b>	<b>122</b>
Non-Infected	-	-	-	-	-	203	399	602
Non-Infected	-	-	-	-	+	1	2	3
Non-Infected	-	-	+	-	-	1	1	2
Non-Infected	-	-	-	+	-	1	1	2
Non-Infected	-	-	+	+	-	0	2	2
Non-Infected	-	+	-	-	-	0	2	2
Non-Infected	-	-	+	+	+	0	1	1
Non-Infected	+	-	-	-	-	1	0	1
Non-Infected	+	+	-	-	+	1	0	1
<b>Total Non-Infected</b>						<b>208</b>	<b>408</b>	<b>616</b>

<sup>a</sup> NAAT1 = BD ProbeTec CT Q<sup>x</sup> and GC Q<sup>x</sup> Amplified DNA Assays, NAAT2 = Gen-Probe APTIMA Combo2 Assay.

<sup>b</sup> Symp = symptomatic, Asymp = asymptomatic.

Note: Subjects are designated as being infected with CT if at least 2 predicate NAATs with different target regions give positive results in the urethral swab and/or the urine specimen.

Note: Subjects with designated infection status and valid **cobas** CT/NG Test results are considered evaluable and included in this summary table.

Note: + denotes Positive; - denotes Negative.

Note: SW = urethral swab, UR= urine.

**Supplementary table 3a** *N.gonorrhoeae* Positive/Negative Analysis for Female Patient Infected Status for the VENUS II trial

Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>			cobas CT/NG Test					Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR	PC Pre	SW	UR	VG	PC Pre	PC Post	Symp	Asymp	
Infected	+	+	+	+	+	+	+	+	+	+	29	37	66
Infected	+	+	+	+	+	+	+	NA	+	+	1	2	3
Infected	+	+	+	-	+	+	+	+	+	+	1	2	3
Infected	+	-	+	-	+	+	-	+	+	+	3	0	3
Infected	+	+	+	+	+	NA	+	+	+	+	1	1	2
Infected	+	+	+	+	-	+	+	+	+	+	0	2	2
Infected	+	+	+	+	+	+	+	+	+	-	1	0	1
Infected	+	+	+	+	+	+	+	+	-	-	0	1	1
Infected	+	+	+	+	+	+	+	-	+	+	1	0	1
Infected	+	+	+	+	+	+	+	-	+	+	1	0	1
Infected	+	+	+	+	+	+	+	NA	+	+	1	0	1
Infected	+	+	+	+	+	NA	NA	NA	+	+	0	1	1
Infected	+	+	+	+	-	-	+	+	+	-	1	0	1
Infected	+	-	+	-	+	+	+	+	+	+	1	0	1
Infected	+	-	+	-	-	+	+	+	+	+	1	0	1
Infected	-	+	+	+	+	+	+	+	+	+	0	1	1
Infected	-	+	+	+	+	+	+	+	-	NA	0	1	1
Infected	-	+	+	+	+	-	+	+	+	+	1	0	1
Infected	-	+	+	+	+	-	+	+	-	-	0	1	1
<b>Total Infected</b>											<b>43</b>	<b>49</b>	<b>92</b>
Non-Infected	-	-	-	-	-	-	-	-	-	-	1704	2709	4413
Non-Infected	-	-	-	-	-	-	-	-	-	NA	62	177	239
Non-Infected	-	-	-	-	-	NA	-	-	-	-	30	36	66
Non-Infected	-	-	-	-	-	-	-	NA	-	-	26	29	55
Non-Infected	-	-	-	-	-	-	NA	-	-	-	24	25	49
Non-Infected	-	-	-	-	NA	-	-	-	NA	NA	18	30	48
Non-Infected	-	-	-	-	-	-	-	-	NA	-	7	37	44
Non-Infected	-	-	-	-	-	-	NA	-	-	NA	3	38	41
Non-Infected	-	-	-	-	-	-	-	-	NA	NA	10	19	29
Non-Infected	-	-	-	-	-	NA	NA	-	-	-	1	18	19
Non-Infected	-	-	-	-	-	NA	-	NA	-	-	2	15	17
Non-Infected	NA	NA	-	-	-	NA	-	-	-	-	0	16	16
Non-Infected	-	-	-	-	-	-	+	-	-	-	5	9	14
Non-Infected	-	-	-	-	-	NA	-	-	-	NA	1	12	13
Non-Infected	+	-	-	-	-	-	-	-	-	-	5	6	11
Non-Infected	-	-	-	-	-	NA	NA	-	-	NA	1	9	10
Non-Infected	NA	-	-	-	-	-	-	-	-	-	3	7	10





Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>			cobas CT/NG Test					Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR	PC Pre	SW	UR	VG	PC Pre	PC Post	Symp	Asymp	

<sup>a</sup> NAAT1 = BD ProbeTec CT Q<sup>x</sup> and GC Q<sup>x</sup> Amplified DNA Assays, NAAT2 = Gen-Probe APTIMA Combo2 Assay.

<sup>b</sup> Symp = symptomatic, Asymp = asymptomatic.

Note: Subjects are designated as being infected with NG if at least 2 predicate NAATs with different target regions give positive results in the endocervical swab and/or the urine specimen. However, females are categorised as non-infected for any swab specimen if the swab specimens and the PreservCyt specimen (NAAT2) were negative and the urine specimens were positive.

Note: Subjects with designated infection status and valid **cobas** CT/NG Test results are considered evaluable and included in this summary table.

Note: + denotes Positive; - denotes Negative; NA indicates specimen was not obtained or available for testing.

Note: SW = endocervical swab, UR = urine, VG = vaginal swab, PC Pre = PreservCyt (pre-aliquot), PC Post = PreservCyt (post-aliquot).

**Supplementary table 3b** *N.gonorrhoeae* Positive/Negative Analysis for Male Patient Infected Status for the VENUS II trial

Patient Infected Status	NAAT1 <sup>a</sup>		NAAT2 <sup>a</sup>		cobas CT/NG Test UR	Symptom Status <sup>b</sup>		Total
	SW	UR	SW	UR		Symp	Asymp	
Infected	+	+	+	+	+	59	7	66
Infected	+	+	-	+	+	1	0	1
<b>Total Infected</b>						<b>60</b>	<b>7</b>	<b>67</b>
Non-Infected	-	-	-	-	-	213	449	662
Non-Infected	-	-	-	-	+	2	3	5
Non-Infected	-	+	-	-	-	1	1	2
Non-Infected	-	-	+	-	-	1	0	1
Non-Infected	+	-	-	-	-	1	0	1
<b>Total Non-Infected</b>						<b>218</b>	<b>453</b>	<b>671</b>

<sup>a</sup> NAAT1 = BD ProbeTec CT Q<sup>x</sup> and GC Q<sup>x</sup> Amplified DNA Assays, NAAT2 = Gen-Probe APTIMA Combo2 Assay.

<sup>b</sup> Symp = symptomatic, Asymp = asymptomatic.

Note: Subjects are designated as being infected with NG if at least 2 predicate NAATs with different target regions give positive results in the urethral swab and/or the urine specimen.

Note: Subjects with designated infection status and valid **cobas** CT/NG Test results are considered evaluable and included in this summary table.

Note: + denotes Positive; - denotes Negative.

Note: SW = urethral swab, UR= urine.